Skip to main content

Table 2 Comparison of three clinical trials of EMA with and without the use of hematopoietic growth factors.

From: Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial

 

EMA[40]

EMA-Placebo[41]

EMA-GM[41]

EMA-G

Patients

133

97

95

29

Median Age

43 (mean)

46

47

51

Status of AML

    

   Refractory or relapsed <1 yr

124 (93%)

61 (64%)*

59 (61%)*

11 (38%)

   Relapsed >1 yr

9 (7%)

36 (36%)

36 (38%)

3 (10%)

Secondary AML

16 (12%)

16 (16%)

13 (14%)

20 (69%)

ANC > 0.5 × 109/L

31 days

37

38

30

CR Rate

60%

59%

65%

46%

Toxic Death

11%

8%

5%

10%

  1. * = Refractory AML plus Relapse AML within 6 months ANC = Time to recover a sustained absolute neutrophil count CR = Complete Remission